TrialEfficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Trial details
- Registry ID
- NCT04455633
- Phase
- Phase 2
LXRX
Lexicon Pharmaceuticals
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633 | Lexicon Pharmaceuticals | Phase 2 | Completed | 2022-05-23Actual |
| Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaNCT04662281 | Lexicon Pharmaceuticals | Phase 2 | Completed | 2022-11-18Actual |
| A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)NCT06203002 | Lexicon Pharmaceuticals | Phase 2 | Completed | 2025-01-14Actual |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891 | Lexicon Pharmaceuticals | Phase 3 | Active not recruiting | 2027-01Estimated |
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Trial details
- Registry ID
- NCT04662281
- Phase
- Phase 2
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Trial details
- Registry ID
- NCT06203002
- Phase
- Phase 2
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Trial details
- Registry ID
- NCT06481891
- Phase
- Phase 3
Latest recorded trial changes
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891 · Lexicon Pharmaceuticals
Primary completion date changed
− Before
Jul 2026
+ After
Jan 2027
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891 · Lexicon Pharmaceuticals
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
NCT04662281 · Lexicon Pharmaceuticals
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change from Baseline in Average Daily Pain Score (ADPS)
+ After
Measure: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS)